Scisparc

Scisparc Equity Ratio

The Equity Ratio of Scisparc (SPRC) as of Oct 17, 2026 is 55.62 %. In the previous year, Equity Ratio was 78.81 % — a change of -29.43% (lower).

Equity Ratio

55.62 %

YoY

-29.43%

Last updated:

Equity Ratio of Scisparc is 2025 55.62 % . Equity Ratio of Scisparc was 2024 78.81 % . It decreases by -29.43% lower compared to the previous year.

The Scisparc Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
4.06 USD
Jan 1, 2019
1.21 USD
Jan 1, 2020
55.84 USD
Jan 1, 2021
82.10 USD
Jan 1, 2022
60.81 USD
Jan 1, 2023
68.09 USD
Jan 1, 2024
78.81 USD
Jan 1, 2025
55.62 USD
The Scisparc Equity Ratio history
YEAREquity RatioYoY
55.62 %-29.43%
78.81 %+15.73%
68.09 %+11.97%
60.81 %-25.93%
82.10 %+47.03%
55.84 %+4,502.61%
1.21 %-70.10%
4.06 %-95.23%
84.97 %+84.67%
46.01 %-41.51%
78.66 %-659.45%
-14.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scisparc Stock analysis

What does Scisparc do? Scisparc Ltd., listed under the ticker SPRC with ISIN IL0010951403, is a biotechnology company headquartered in Tel Aviv-Yafo, Israel. The company operates in the healthcare sector and has a workforce of three employees. Scisparc Ltd. went public through an IPO on December 22, 2021. Its website is https://scisparc.com/. The company is engaged in the development of pharmaceutical products based on cannabinoid technologies, focusing on repurposing dronabinol for various medical conditions. Specific drug development programs include THX-110 for Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for infectious diseases; and THX-160 for pain treatment. Scisparc Ltd. is a clinical stage pharmaceutical company, indicating its focus on advancing drug candidates through clinical trials toward potential regulatory approval and commercialization. The company's activities are centered around leveraging cannabinoid-based approaches to address unmet medical needs in multiple therapeutic areas. Scisparc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scisparc stock

Equity Ratio of Scisparc is 55.62 % in 2025.

Equity Ratio of Scisparc changed from 78.81 % to 55.62 %, representing a -29.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Scisparc since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Scisparc with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Scisparc

All Key Metrics — Scisparc